In order to optimize your use of our website we use cookies. If you want more information about our cookie policy, please read more here. By continuing, you agree to our use of cookies.

Close

logo

English
  • Svenska
  • About us
    About us
      • This is Calliditas
      • Vision and Strategy
      • Our Pipeline
      • Board of Directors
      • Management Team
      • Our History
      • Corporate Responsibility
      • Career
  • Disease overview
    Disease overview
      • IgA nephropathy
      • Nefecon
      • Orphan drugs
      • Other potential indications
      • Scientific Advisory Board
      • Clinical trials
        • Development program
  • Governance
    Governance
      • Corporate Governance
      • Corporate Governance Reports
      • Corporate Structure
      • General Meeting
        • Annual general meeting 2020
        • General meetings
      • Nomination Committee
        • Nomination committees
      • Board and Committees
        • Board of Directors
        • Board fees
        • Work of the Board of Directors
        • Committees
      • Management
        • Management team
      • Remuneration
      • Internal control and risk management
      • Auditor
      • Articles of Association
  • Investors
    Investors
      • The share
        • Trading information
        • Ownership structure
        • Share capital development
        • Dividend policy
        • Analyst coverage
      • Financial Reports and Presentations
      • SEC Filings
      • Archive old prospectuses
      • Press releases
      • Calendar
      • Subscribe
      • Contacts
      • Investor FAQs
      • Documentation Genkyotex tender offer
      • Capital Markets Day 2021
  • Media
    Media
      • Press releases
      • Calliditas in Media
      • Subscribe
      • Contacts
  • Contacts
    Contacts
      • Offices
      • Partnering
      • Investors
      • Media
  • Capital Markets Day 2021
  • Svenska

Calendar

Upcoming events
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
Add to calendar
Feb 18, 2021

Year-end report for the period January 1 – December 31, 2020

Add to calendar
Apr 27, 2021

Annual Report 2020

Add to calendar
May 13, 2021

Interim report for the period January 1 – March 31, 2021

Add to calendar
May 27, 2021

Annual General Meeting 2021

Add to calendar
Aug 19, 2021

Interim report for the period January 1 – June 30, 2021

Add to calendar
Nov 18, 2021

Interim report for the period January 1 – September 30, 2021

Add to calendar
Feb 24, 2022

Year-end report for the period January 1 – December 31, 2021

Add to calendar
  • Investors
    • The share
      • Trading information
      • Ownership structure
      • Share capital development
      • Dividend policy
      • Analyst coverage
    • Financial Reports and Presentations
    • SEC Filings
    • Archive old prospectuses
    • Press releases
    • Calendar
    • Subscribe
    • Contacts
    • Investor FAQs
    • Documentation Genkyotex tender offer
    • Capital Markets Day 2021

Calliditas Therapeutics AB
Kungsbron 1, C8
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

  • Privacy policy
  • About cookies

© Calliditas Therapeutics AB 2021